Gilead Sciences Inc. (GILD)

65.74
NASDAQ : Health Technology
Prev Close 65.55
Day Low/High 65.33 / 65.96
52 Wk Low/High 60.32 / 82.72
Avg Volume 7.51M
Exchange NASDAQ
Shares Outstanding 1.28B
Market Cap 84.04B
EPS 4.20
P/E Ratio 9.83
Div & Yield 2.52 (3.40%)

Latest News

An Interesting Week For Dividends

An Interesting Week For Dividends

It's behavioral finance at its finest, and makes for a fascinating debate.

Gilead Shares Fall After Hours as Company Misses on Quarterly Earnings

Gilead Shares Fall After Hours as Company Misses on Quarterly Earnings

Medicine is a slow business and I view Gilead Sciences as a hold for now.

What the Super Bowl Can Teach Us About Our Portfolio: Market Recon

What the Super Bowl Can Teach Us About Our Portfolio: Market Recon

And why maintaining a small position in defense stocks is important.

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

And it is happening not a moment too soon.

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

3 Profitable Small Biotech Names to Consider

3 Profitable Small Biotech Names to Consider

Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.

Gilead Sciences Is Sporting a Bearish Set of Charts for Investors

Gilead Sciences Is Sporting a Bearish Set of Charts for Investors

Gilead has been trying to turn things around but few see that turn coming anytime soon.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Be Ready to Ride the Dividend on Gilead Sciences

Be Ready to Ride the Dividend on Gilead Sciences

There are no catalysts to drive the stock price higher, so for now, Gilead is simply a cheap stock with a nice dividend.

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

It becomes difficult for me to tell you where to run in these markets...

Gilead Has Strengthened So Go Long and Add to Longs

Gilead Has Strengthened So Go Long and Add to Longs

Traders who are already long Gilead should buy more and if you are flat this is a good location to go long.

Gilead's Earnings Fail to Impress

Gilead's Earnings Fail to Impress

The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.

Biotech Stocks Rally on Biogen's Landmark Test

Biotech Stocks Rally on Biogen's Landmark Test

Investors might be finally recognizing the hidden value of the firms' drug research and development.

Gilead Sciences Is Displaying a Bullish Long-Term Pattern

Gilead Sciences Is Displaying a Bullish Long-Term Pattern

This biotech's weekly chart is very encouraging.

Jim Cramer: Confounding Days

Jim Cramer: Confounding Days

The buyers of stocks on days like Tuesday make very little sense.

Jim Cramer: A GLUM Index For Gloomy Markets

Jim Cramer: A GLUM Index For Gloomy Markets

Taking the measure of what's keeping the markets in the dumps.

Galmed Soars on Encouraging Trial Results

Markets have perked up just a tad across the board since our last update. As mentioned in an earlier post, Galmed Pharmaceuticals is the second small-cap NASH (nonalcoholic steatohepatitis) play that has soared over the past week. The shares are up ...

Jim Cramer: Move Over FANG, Long Live INJFANG

Jim Cramer: Move Over FANG, Long Live INJFANG

The Nasdaq hit an all-time high today, and It's Not Just FANG anymore.

Jim Cramer: I Don't Have a Catalyst for Celgene or Gilead

Jim Cramer: I Don't Have a Catalyst for Celgene or Gilead

After analyzing the biotech space, TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't have a catalyst for Celgene or Gilead.

Surveying the M&A Landscape in Biotech

Surveying the M&A Landscape in Biotech

Who might be in play in the quarters ahead?

Are Apple's Best Days in the Past?: Market Recon

Are Apple's Best Days in the Past?: Market Recon

I think it very possible that there will be a positive reaction tonight, more likely based on what Tim Cook says.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Which Hot Biotech Name Will Be Acquired Next?

Which Hot Biotech Name Will Be Acquired Next?

Your burning biotech questions answered in our latest mailbag.

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.